[Federal Register Volume 76, Number 75 (Tuesday, April 19, 2011)]
[Notices]
[Page 21916]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-9370]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on December 14, 2010, Norac 
Inc., 405 S. Motor Avenue, P.O. Box 577, Azusa, California 91702-3232, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the following basic 
classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)...........  I
Tetrahydrocannabinols (7370)...............  I
Methamphetamine (1105).....................  II
Pentobarbital (2270).......................  II
Nabilone (7379)............................  II
------------------------------------------------------------------------

    With regard to Gamma Hydroxybutyric Acid (2010), 
Tetrahydrocannabinols (7370), and Methamphetamine (1105) only, the 
company manufactures these controlled substances in bulk solely for 
domestic distribution within the United States to customers engaged in 
dosage-form manufacturing.
    With regard to Nabilone (7379) only, the company presently 
manufactures a small amount of this controlled substance in bulk solely 
to conduct manufacturing process development internally within the 
company. It is the company's intention that, when the manufacturing 
process is refined to the point that its Nabilone bulk product is 
available for commercial use, the company will export the controlled 
substance in bulk solely to customers engaged in dosage-form 
manufacturing outside the United States. The company is aware of the 
requirement to obtain a DEA registration as an exporter to conduct this 
activity.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than June 20, 2011.

    Dated: April 11, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2011-9370 Filed 4-18-11; 8:45 am]
BILLING CODE 4410-09-P